At the Clinical Trials Plenary Session at the 2022 AACR Annual Meeting, Dr. John Haanen, M.D., Ph.D., of the Netherlands Cancer Institute presented data from BioNTech’s ongoing first-in-human Phase I/II trial of the company’s CAR-T cell therapy BNT211 in patients with advanced solid tumors.
Researchers from the Karolinska Institute in Sweden and University Children’s Hospital, Ruhr-University-Bochum, Germany, studied the impact of Covid-19 infections on lung function.
Data from Johns Hopkins University demonstrate that daily Covid-19 infections increased 316 percent from Labor Day 2020, or about four times more.
A new study may help explain why mRNA vaccines by Pfizer/BioNTech and Moderna are more effective at preventing hospitalizations and deaths than they are at preventing infection. In another study, preliminary data suggests certain cancer drugs may help protect patients with malignancies from being infected with the new coronavirus.
Moderna believes the company’s Covid-19 vaccine protects against new variants found in Britain and South Africa, although it will test a new booster shot aimed at the South Africa variant after concluding that the antibody response could be diminished.
Passage Bio’s first attempt to develop a GM1 gangliosidosis gene therapy treatment ran into a roadblock in the form of a clinical hold.
Researchers at the University of Pennsylvania School of Medicine found that certain changes in DNA sequences can trigger the resulting genome to misfold in such a way that the person is at increased risk for Type 1 diabetes.
Researchers with the Abramson Cancer Center of the University of Pennsylvania, led by Carl June, published results from the first U.S. Phase I trial of CRISPR-Cas9-edited T-cells in humans with advanced cancer.
Eagle Pharmaceuticals Inc. and the University of Pennsylvania agreed on terms of a new exclusive worldwide license agreement for the development of dantrolene sodium for the potential treatment of people living with Alzheimer’s disease.
Cranbury, N.J.-based Amicus Therapeutics and the Perelman School of Medicine at the University of Pennsylvania are expanding their gene therapy collaboration.